A report variety of individuals within the U.S. will flip 65 this yr. Here’s how the phenomenon referred to as Peak 65 can have an effect on you, even in case you are not near that age.
Beth Pinsker interviews a lady who will flip 65 in June however started worrying about retirement funds again in 1981. Here’s what she discovered and what she is specializing in now.
Jessica Hall interviews one other girl who turns 65 this yr and is discovering her second, part-time profession rather more fulfilling than her first one.
Read on: Medicare, and different pitfalls of turning 65
Help with funds earlier than and through retirement
Getting these choices proper could make or prevent some huge cash over the lengthy haul.
MarketWatch photograph illustration/iStockphoto
Alessandra Malito writes the Help Me Retire column. This week she solutions questions from a 52-year-old about Roth IRAs and index funds. She additionally helps a 73-year-old with questions on required minimal distributions from a tax-deferred retirement account.
Brett Arends covers numerous retirement-related topics:
- Citi neglected its govt’s elder fraud for 9 years. What else may we be lacking?
- Does Viagra actually assist forestall Alzheimer’s? Not so quick.
Stocks for the Super Bowl
A win by which crew can be a greater indicator for the inventory market’s efficiency?
Getty Images
Just in time for the massive sport, Mark Hulbert appears again to see how effectively a “Super Bowl Indicator” has predicted the motion of the inventory market.
Hulbert additionally appears at Fortune’s listing of the “world’s most admired companies” to see how a lot this coveted rating correlates to the motion of inventory costs. The outcomes of his evaluation could shock you.
Diving for dividend shares
When buyers contemplate dividend-paying shares, they could start by wanting on the ones with the best dividend yields. But there’s one other strategy which may be a greater for constructing a profitable earnings stream over the long run.
More: Is Meta now a price inventory?
This might be a inexpensive method for buyers to earn a living from the weight-loss-drug craze
Speculative buyers may discover a larger reward, with extra danger, with shares of Viking Therapeutics as a play on the GLP-1 weight-loss-drug craze.
MarketWatch/Viking Therapeutics
Shares of Elli Lilly & Co.
LLY,
the maker of Mounjaro, a GLP-1 weight-loss drug, have greater than doubled over the previous yr and commerce for 56.4 occasions the consensus earnings-per-share estimate over the subsequent 12 months, amongst analysts polled by FactSet. In comparability, the S&P 500 trades for a weighted 20.4 occasions its ahead EPS estimate.
American depositary receipts of rival Novo Nordisk A/S
NVO,
which makes Wegovy and Ozempic, have returned 71% over the previous yr and now commerce at a ahead price-to-earnings ratio of 35.
Among analysts polled by FactSet, 74% charge Eli Lilly a purchase or the equal, however their consensus worth goal of $740.79 was only one% above the inventory’s closing worth of $735.68 on Thursday. For Novo Nordisk, 60% of analysts have purchase scores on the ADR, and their worth goal of $116.17 was barely under Thursday’s closing worth of $118.39.
So the analysts like the businesses however consider their shares are totally valued, at the least for the subsequent yr.
Ciara Linnane explains why analysts are in love with Viking Therapeutics Inc.
VKTX,
which has moved up the schedule for trials of its personal GLP-1 receptor agonist treatment. All 10 analysts masking the corporate who have been polled by FactSet charge the inventory a purchase, and their consensus worth goal of $36.33 was 26% above Thursday’s closing worth of $28.89.
Drugmakers deflect blame to middlemen for prime costs
Sen. Bernie Sanders had a bone to select with giant drug producers on Thursday.
Getty Images
During a Senate Health, Education, Labor and Pensions Committee listening to on Thursday, Sen. Bernie Sanders, the Vermont unbiased, and others grilled the chief executives of Johnson & Johnson
JNJ,
Merck & Co.
MRK,
and Bristol Myers Squibb Co.
BMY,
about excessive drug costs. The CEOs pushed again with numbers to put blame elsewhere, as Eleanor Laise stories.
More biotech and pharmaceutical protection:
A brand new marketplace for tech employees
Support teams on LinkedIn are rising for employees displaced as know-how firms lay off hundreds.
WALL STREET JOURNAL, GETTY IMAGES
James Rogers covers a tough topic — mounting layoffs by know-how firms — and stories on the brand new assist teams which are serving to individuals discover new jobs.
More from James Rogers:
Big strikes for householders
Aarthi Swaminathan writes the Big Move column to assist readers with sophisticated real-estate questions. This week she addresses two tough eventualities:
- My mom, 87, has $425,000 left on a house value $1 million. How can I settle her money owed when she passes? Should I take out a reverse mortgage?
- ‘I’m dipping into my Roth IRA’: I’ve been unemployed for 5 months. I used to earn $10,000 a month. Do I promote my home?
NYCB’s inventory slide reverses
Shares of New York Community Bancorp have been down 59% for 2024 by Thursday, earlier than reversing on Friday.
MarketWatch photograph illustration/Google
Steve Gelsi has been reporting in regards to the difficulties at New York Community Bancorp Inc.
NYCB,
which shocked buyers final week with a larger-than anticipated fourth-quarter provision for loan-loss reserves and a drastic dividend lower. Here’s Gelsi’s newest abstract of the persevering with occasions, together with a pointy reversal of NYCB’s share-price slide on Friday.
A robust stretch for shares, and a warning
Joseph Adinolfi explains that the U.S. inventory market hasn’t carried out this effectively, by this measure, since 1972.
Related: S&P 500 reaches 5,000 for first time. Here’s what it means for the market.
More assist from the Moneyist
MarketWatch illustration
We all may choose to keep away from tough questions on cash from family and friends. Quentin Fottrell — the Moneyist — does the other:
Want extra from MarketWatch? Sign up for this and different newsletters to get the newest news and recommendation on private finance and investing.
Source web site: www.marketwatch.com
